Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L P Bos

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
The Netherlands Journal of Medicine|April 1, 1989
Clinical relevance of lysozyme in the faecesM H Hemrika, G M Costongs, L G Engels, et al.
The Netherlands Journal of Medicine|August 1, 1989
Sucralphate-technetium scintigraphy in inflammatory bowel disease: experience in 23 patientsR N Zeijen, H A van der Pol, G J Teule, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|August 14, 1987
Faecal lysozyme: determination, reference intervals and some data in gastro-intestinal diseaseG M Costongs, M H Hemrika, L G Engels, et al.
Clinical Drug Investigation|May 26, 2007
Therapeutic drug monitoring in patients with inflammatory bowel disease and established azathioprine therapyL P L Gilissen, L J J Derijks, L P Bos, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 26, 2006
Toxicity of 6-thioguanine: no hepatotoxicity in a series of IBD patients treated with long-term, low dose 6-thioguanine. Some evidence for dose or metabolite level dependent effects?L P L Gilissen, L J J Derijks, A Driessen, et al.
Diseases of the Colon and Rectum|March 24, 1998
High incidence of inflammatory bowel disease in The Netherlands: results of a prospective study. The South Limburg IBD Study GroupM G Russel, E Dorant, A Volovics, et al.
Alimentary Pharmacology & Therapeutics|September 27, 2005
The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patientsL P L Gilissen, J Bierau, L J J Derijks, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
The Netherlands Journal of Medicine|April 1, 1989
Clinical relevance of lysozyme in the faecesM H Hemrika, G M Costongs, L G Engels, et al.
The Netherlands Journal of Medicine|August 1, 1989
Sucralphate-technetium scintigraphy in inflammatory bowel disease: experience in 23 patientsR N Zeijen, H A van der Pol, G J Teule, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|August 14, 1987
Faecal lysozyme: determination, reference intervals and some data in gastro-intestinal diseaseG M Costongs, M H Hemrika, L G Engels, et al.
Clinical Drug Investigation|May 26, 2007
Therapeutic drug monitoring in patients with inflammatory bowel disease and established azathioprine therapyL P L Gilissen, L J J Derijks, L P Bos, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 26, 2006
Toxicity of 6-thioguanine: no hepatotoxicity in a series of IBD patients treated with long-term, low dose 6-thioguanine. Some evidence for dose or metabolite level dependent effects?L P L Gilissen, L J J Derijks, A Driessen, et al.
Diseases of the Colon and Rectum|March 24, 1998
High incidence of inflammatory bowel disease in The Netherlands: results of a prospective study. The South Limburg IBD Study GroupM G Russel, E Dorant, A Volovics, et al.
Alimentary Pharmacology & Therapeutics|September 27, 2005
The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patientsL P L Gilissen, J Bierau, L J J Derijks, et al.
Pageof 2